We conducted this Early AMPLE study to further explore this observation and identify any novel characteristics that further define the features of an RA subpopulation that could potentially derive additional benefit from treatment with abatacept over a TNF inhibitor such as adalimumab. Here, TNF is linked to rheumatoid arthritis.